Biotech Values

[DewDiligence]

MNTA/TEVA—I was asked on another board whether the Court ruling in #msg-63573604 changes the odds in the Copaxone patent case. The answer, IMO, is: yes, but not by enough to worry about.

As can be seen in the table in #msg-59688565 (from Feb 2011), I figured there was only a 5% probability that NVS/MNTA would prevail on the inequitable conduct argument, specifically. This probability should now be somewhat lower, but the decrease amounts to round-off error, IMO.